Opyl taking two steps to revolutionise clinical trials this year

Opyl is on a mission to improve the $US19.2 billion global clinical trials market with two innovative platforms that will be launching soon.

“Good medical research discoveries often don’t make it to the market because they are not given the best chance to succeed, either due to poor design or poor implementation… that’s billions of dollars a year, not delivering a return for investors or patients.” – CEO Michelle Gallaher.

This is only an excerpt from an article written by Stockhead. The full version can be found here.